OraSure Technologies, Inc.
OraSure Technologies, Inc.
- Market cap
- $238.90M
Your view on OSUR
Overview
What the company does, where it operates, and who runs it.
About OraSure Technologies, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Carrie Eglinton Manner
- Headquarters
- 220 East First Street, Bethlehem, PA, US
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Carrie Eglinton Manner
- Headquarters
- 220 East First Street, Bethlehem, PA, US
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions.
The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test.
It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services.
In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing.
Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities.
OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for OraSure Technologies, Inc.. Starting points for OraSure Technologies, Inc.: EPS -$0.70, beta 1.06 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for OraSure Technologies, Inc.. Trailing twelve-month EPS for OraSure Technologies, Inc. stands at -$0.70. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for OraSure Technologies, Inc.. OraSure Technologies, Inc. has reported as a listed company since 1986. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| NNCSFNanosonics Limited | Healthcare | OTC | $697.7M | ||
| NNNNAnbio Biotechnology Class A Ordinary Shares | Healthcare | NASDAQ | $145.7M | ||
| NPRRFNipro Corporation | Healthcare | OTC | $1.3B | ||
| NVSTEnvista Holdings Corp | Healthcare | NYSE | $3.7B | ||
| NXGLNEXGEL, Inc. | Healthcare | NASDAQ | $1.7M | ||
| NXGLWNEXGEL, Inc. | Healthcare | NASDAQ | $550,561 | ||
| OJSYOJsys, Inc. | Healthcare | OTC | $454,285 | ||
| OSX.AXOsteopore Limited | Healthcare | ASX | — | ||
| OTC.VOcumetics Technology Corp. | Healthcare | TSXV | $32.9M | ||
| OTCFFOcumetics Technology Corp. | Healthcare | OTC | $16.0M | ||
| PDEXPro-Dex, Inc. | Healthcare | NASDAQ | $201.6M | ||
| PDMIParadigm Medical Industries, Inc. | Healthcare | OTC | $324,879 | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold OraSure Technologies, Inc., and how their positions are changing. At a $238.9M market value, institutional positions materially move OraSure Technologies, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by OraSure Technologies, Inc. executives and directors. Shares of OraSure Technologies, Inc. have traded between $2.10 and $4.22 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming OraSure Technologies, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for OraSure Technologies, Inc.. Coverage tracks OraSure Technologies, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of OraSure Technologies, Inc.